Hybio Pharmaceutical Co., Ltd. (300199.SZ)
300199.SZ Stock Price Chart
Explore Hybio Pharmaceutical Co., Ltd. interactive price chart. Choose custom timeframes to analyze 300199.SZ price movements and trends.
300199.SZ Company Profile
Discover essential business fundamentals and corporate details for Hybio Pharmaceutical Co., Ltd. (300199.SZ) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
7 Apr 2011
Employees
895.00
Website
https://www.hybio.com.cnCEO
Yu Pinxiang
Description
Hybio Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of therapeutic peptides API and polypeptide drugs in China and internationally. The company provides liraglutide, semaglutide and exenatide for diabetes; terlipressin, desmopressin and linaclotide for digestive tract and metabolic system; ganirelix, cetrorelix and atosiban for obstetrics and gynecology, etc; customized peptides; working standards for the peptide APIs and related impurities, to facilitate your project in an all-round way; CRO services; and platform for CDMO services, which includes peptide API synthesis and purification process development, finish dosage form development, reference standard preparation and qualification, impurity and product quality study and analysis, GMP system meeting EU and FDA standard, international and Chinese regulatory and dossier support, etc. Hybio Pharmaceutical Co., Ltd. was founded in 1998 and is headquartered in Shenzhen, China.
300199.SZ Financial Timeline
Browse a chronological timeline of Hybio Pharmaceutical Co., Ltd. corporate events including earnings releases, dividend announcements, and stock splits.
Earnings released on 25 Apr 2025
EPS came in at ¥0.08 , while revenue for the quarter reached ¥309.97M .
Earnings released on 26 Mar 2025
EPS came in at -¥0.15 , while revenue for the quarter reached ¥214.97M .
Earnings released on 29 Oct 2024
EPS came in at -¥0.03 , while revenue for the quarter reached ¥119.50M .
Earnings released on 23 Aug 2024
EPS came in at ¥0.00 , while revenue for the quarter reached ¥102.37M .
Earnings released on 27 Apr 2024
EPS came in at -¥0.02 , while revenue for the quarter reached ¥148.81M .
Earnings released on 22 Feb 2024
EPS came in at -¥0.40 , while revenue for the quarter reached ¥29.83M .
Earnings released on 27 Dec 2023
EPS came in at -¥0.17 , while revenue for the quarter reached ¥76.28M .
Earnings released on 30 Jun 2023
EPS came in at -¥0.06 , while revenue for the quarter reached ¥149.06M .
Earnings released on 31 Mar 2023
EPS came in at ¥0.02 , while revenue for the quarter reached ¥176.22M .
Earnings released on 1 Jan 2023
EPS came in at -¥0.29 , while revenue for the quarter reached ¥173.36M .
Earnings released on 30 Sept 2022
EPS came in at -¥0.05 , while revenue for the quarter reached ¥174.43M .
Earnings released on 30 Jun 2022
EPS came in at -¥0.05 , while revenue for the quarter reached ¥189.32M .
Earnings released on 22 Apr 2022
EPS came in at ¥0.17 , while revenue for the quarter reached ¥228.24M .
Earnings released on 31 Mar 2022
EPS came in at -¥0.06 , while revenue for the quarter reached ¥167.21M .
Earnings released on 30 Sept 2021
EPS came in at -¥0.10 , while revenue for the quarter reached ¥141.55M .
Earnings released on 30 Jun 2021
EPS came in at -¥0.06 , while revenue for the quarter reached ¥187.60M .
Earnings released on 29 Apr 2021
EPS came in at -¥0.73 , while revenue for the quarter reached ¥34.24M .
Earnings released on 31 Mar 2021
EPS came in at ¥0.03 , while revenue for the quarter reached ¥178.57M .
Earnings released on 28 Oct 2020
EPS came in at ¥0.01 , while revenue for the quarter reached ¥247.33M .
300199.SZ Stock Performance
Access detailed 300199.SZ performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.